CRISPR-Cas systems protect prokaryotes against viruses and other foreign nucleic acids. This protection is adaptive and sequence specific due to crRNA molecules that recognize the targets and guide the effector complex to them. It is known that type I, II and V effector complexes (Cascade, Cas9-RNA and Cpf1-RNA, respectively) cleave foreign DNA while type III and VI complexes (Csm/Cmr and Cas13) degrade foreign RNA [1]. Additionally, binding of target RNA by the type III complexes activates their Cas10 subunit to degrade DNA [2] and synthesize cyclic oligoadenylates from ATP. The cyclic oligoadenylates serve as unique messengers that activate a stand-alone ribonuclease Csm6 [3, 4]. In this study we aimed to understand the regulation of Csm6 from Streptococcus thermophilus. For this, we optimised the protein expression and purification protocols and performed screening of crystallisation conditions. We employed RNA cleavage assays to determine suitable ligands and evaluate the quality of purified proteins. Understanding of the Csm6 structural changes could lead to improvement of the controllable ribonuclease and design of novel regulable proteins.
CSM6 - THE LATENT RIBONUCLEASE IN CYCLIC OLIGOADENYLATE SIGNALLING PATHWAY
Miglė Kazlauskienė1, Augustė Rimaitė1, Giedrė Tamulaitienė1, Gintautas Tamulaitis1, Virginijus Šikšnys1
1 Institute of Biotechnology, Life Sciences Center, Vilnius University, Lithuania
[1] Koonin, E. V., Makarova, K. S., Zhang, F. Diversity, classification and evolution of CRISPR-Cas systems. Curr. Opin. Microbiol. 37, 67–78 (2017).
[2] Kazlauskiene, M., Tamulaitis, G., Kostiuk, G., Venclovas, Č., Siksnys, V. Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition. Mol. Cell 62, 295–306 (2016).
[3] Kazlauskiene, M., Kostiuk, G., Venclovas, Č., Tamulaitis, G., Siksnys, V. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. Science 357, 605-609 (2017).
[4] Niewoehner, O., García-Doval, C., Rostøl, J. T., Berk, C., Schwede, F., Bigler, L., Hall, J., Marraffini, L. A., Jinek, M. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers. Nature 548, 543–548 (2017).